NCT00095745

A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

A Multicenter, Long-Term, Open-label, Study to Assess the Safety and Tolerability of Aripiprazole as an Adjunctive Therapy in the Treatment of Outpatients With Major Depressive Disorder

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,002 (actual)
• Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in outpatients with major depressive disorder who have experienced an incomplete response to an ongoing antidepressant trial.

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	Antidepressant + Aripiprazole	Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-30mg Aripiprazole, once daily, 52-weeks.

Timeline

• Start date: 2004-09-01
• Primary completion: 2007-11-01
• Completion: 2007-11-01
• First posted: 2004-11-09
• Last updated: 2013-11-08

Locations

58 sites across 1 country: United States